Background.
Trypanosoma brucei Sadenosylmethionine decarboxylase (AdoMetDC) is activated by heterodimerization with a catalytically dead paralog, prozyme.
Results. Trypanosomatid-specific residues in the AdoMetDC N-terminus are essential for prozymemediated activation, but not for heterodimerization.
Conclusions. AdoMetDC activation likely involves a conformational change of the Nterminal peptide.
Significance. Development of conformationallysensitive AdoMetDC inhibitors may provide a species-selective mechanism to inhibit trypanosomatid AdoMetDCs.
SUMMARY
Human African trypanosomiasis (HAT) is caused by a single-celled protozoan parasite, Trypanosoma brucei. Polyamine biosynthesis is a clinically validated target for the treatment of HAT. Metabolic differences between the parasite and the human polyamine pathway are thought to contribute to species selectivity of pathway inhibitors. S-adenosylmethionine decarboxylase (AdoMetDC) catalyses a key step in the production of the polyamine spermidine. We previously showed that trypanosomatid AdoMetDC differs from other eukaryotic enzymes in that it is regulated by heterodimer formation with a catalytically dead paralog, designated prozyme, which binds with high affinity to the enzyme and increases its activity by up to 10 3 -fold. Herein, we examine the role of specific residues involved in AdoMetDC activation by prozyme through deletion and site-directed mutagenesis. Results indicate that 12 key amino acids at the Nterminus of AdoMetDC are essential for prozymemediated activation, with Leu-8, Leu-10, Met-11 and Met-13 identified as the key residues. These N-terminal residues are fully conserved in the trypanosomatids but are absent from other eukaryotic homologs lacking the prozyme mechanism, suggesting co-evolution of these residues with the prozyme mechanism. Heterodimer formation between AdoMetDC and prozyme was not impaired by mutation of Leu-8 and Leu-10 to Ala, suggesting that these residues are involved in a conformational change that is essential for activation. Our findings provide the first insight into the mechanisms that influence catalytic regulation of AdoMetDC, and may have potential implications for the development of new inhibitors against this enzyme.
INTRODUCTION
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a vector-borne parasitic disease caused by the protozoan pathogen T. brucei (1, 2) . The World Health Organization (WHO) estimates that up to 50 million people in Sub-Saharan Africa are at risk, with reported yearly infections in the tens of thousands (3) . HAT is characterized by severe neurological symptoms that lead to coma and eventual death in nearly all untreated individuals (4, 5) . The WHO has increased surveillance and control of African trypanosomiasis (6) , however one of the greatest remaining challenges to eliminating HAT is the lack of safe and effective therapies (7) (8) (9) . The recent introduction of NECT therapy (nifurtimoxeflornithine combination therapy) has improved management of late-stage disease (10) , but it is a difficult therapy to administer and is not effective against all species of the parasite. Eflornithine, also known as α-difluoromethylornithine (DFMO), is a suicide inhibitor of ornithine decarboxylase (ODC), implicating polyamine biosynthesis as a key target for HAT therapy.
Polyamines are small organic cations that are required for cell growth and which play important roles in diverse cellular processes such as replication, transcription and translation (11) (12) (13) . The key steps in polyamine biosynthesis are catalyzed by ODC, which leads to formation of putrescine, and by the pyruvoyl-dependent Sadenosylmethionine decarboxylase (AdoMetDC), which catalyzes the decarboxylation of AdoMet to produce the aminopropyl group required for synthesis of spermidine from putrescine (Scheme 1) (14) . Human AdoMetDC is a α 2 β 2 homodimer, and the active sites that contain the covalentlybound pyruvate cofactor sit in a cleft between β-sheets oriented away from the dimer interface ( Fig. 1A) (15, 16) . The pyruvate is generated by an auto processing reaction that also leads to cleavage of the peptide bond into the α and β chains (17, 18) . Putrescine stimulates both the processing and decarboxylation reactions of the mammalian enzyme (15, 18) .
Polyamine metabolism in trypanosomatids is unique and differences with the human enzyme are thought to contribute to selective toxicity of inhibitors that target the pathway (19-22). These include differences in protein turnover rates and the finding that spermidine is conjugated to glutathione, forming a novel molecule termed trypanothione, which is required for redox chemistry. Genetic and chemical studies have demonstrated that polyamine and trypanothione biosynthetic enzymes are essential for T. brucei growth (20) and, in addition to DFMO, inhibitors of AdoMetDC and trypanothione synthetase (TS) showing good anti-trypanosomal activity have also been described (23-25).
Polyamine levels are tightly controlled throughout the cell cycle in eukaryotes, but the regulatory mechanisms established in other eukaryotes are not found in T. brucei (26,27). We showed previously that the trypanosomatid AdoMetDC is allosterically activated by heterodimer formation with a catalytically dead paralog, designated prozyme, which is present only in the trypanosomatids (28). Prozyme is neither processed to generate the pyruvute cofactor, nor does it display catalytic activity. However, upon binding, prozyme stimulates AdoMetDC activity by ~10 3 -fold. Putrescine, which stimulates the activity of human AdoMetDC, does not affect the activity of the T. brucei heterodimer (15) , however it is required for the T. cruzi heterodimer to reach full activation (29). In T. brucei, prozyme expression levels appear to be translationally regulated in response to inhibition or knockdown of AdoMetDC, suggesting that the parasite controls polyamine synthesis at least in part through this mechanism (30).
The structural basis for the activation of trypanosomatid AdoMetDC by prozyme remains an open question as no structural data is available for any of the trypanosomatid enzymes. To gain insight into this question, we evaluated the role of trypanosomatid specific amino acid residues in the prozyme-mediated activation of T. brucei AdoMetDC through deletion and site-directed mutagenesis. Results indicate that the unique trypanosomatid N-terminal 16-amino acid peptide of AdoMetDC is essential for this process. We found that deletion of these residues led to a loss of prozyme activation. Subsequent site-directed mutagenesis identified two Leu residues (8 and 10) and two Met residues (11 and 13) necessary for prozyme activation. Interestingly, unlike the wild-type heterodimeric enzyme, the L8A and L10A mutant enzymes were activated by putrescine, though activity remained below the fully functional wild-type enzyme. Sedimentation velocity experiments demonstrate that mutation of L8 or L10 to Ala does not impair heterodimer formation suggesting that these residues are involved in a conformational change that is essential for activation. The 16 amino acid unique N-terminus is partially conserved in prozyme, but deletion of these residues in prozyme did not significantly affect activity. Our findings provide the first insight into the structural basis and mechanisms that control AdoMetDC activation by prozyme, demonstrating the importance of a unique N-terminal peptide in the process. Table S1 .
EXPERIMENTAL PROCEDURES
E. coli TOP10 competent cells were transformed with each plasmid, and mutations were confirmed by DNA sequencing.
AdoMetDC/prozyme expression and purification. E.coli BL21/DE3 cells were transformed with the construct of interest and grown at 37°C until OD 600 reached between 0.6 -0.8. Protein expression was induced by the addition of 0.2 mM IPTG and cells grown O/N at 20°C. Cells were harvested by centrifugation and resuspended in lysis buffer (50mM Hepes, 100mM NaCl, 10mM imidazole, 5mM β-mercaptoethanol). Protease inhibitors were added directly to the cell lysate (Cocktail 1 (1:1000) -1 mg/mL Leupeptin, 2mg/mL Antipain and 10 mg/mL Benzamidine; Cocktail 2 (1:1000) -1 mg/mL Pepstain, 1mg/mL Chymostatin; and 0.2 M Phenylmethyl-sylfonyl fluoride (PMSF) in a 1:500 ratio) (Sigma, St.Louis, MO). Bacterial cells were lysed using an EmulsiFlex-C5 homogenizer, followed by centrifugation (Beckman Ti-45 rotor) at 15,000 rpm for 30 min. The soluble fraction was subjected to Ni 2+ -agarose (Qiagen, Valencia, CA) column chromatography (buffer A: 50mM Hepes pH 8.0, 100 mM NaCl, 1 mM β-mercaptoethanol, 10 mM imidazole; buffer B: 50 mM Hepes pH 8.0, 100 mM NaCl, 1 mM β-mercaptoethanol, 800 mM imidazole), as previously described (28,31). Heterodimeric enzymes were obtained by mixing the separate lysates and co-purifying the His 6 -SUMO-tagged AdoMetDC with the Flag-tagged wild-type prozyme or tagless Δ25 prozyme. AdoMetDC containing fractions were pooled together, concentrated and diluted back in buffer A, to remove excess imidazole. The protein sample was then incubated with ULP1 (below), also known as SUMO protease 1, which recognizes the tertiary structure of SUMO in the fusion protein and cleaves with high specificity. This resulted in the removal of the His 6 -SUMO tag generating AdoMetDC such that no tag region remained. AdoMetDC (wild-type or mutant) sample was incubated with approximately 300 µg of ULP1 for every 20 -35 mg AdoMetDC for 2 h at 4°C with gentle agitation. After cleavage, a second Ni 2+ -agarose purification step was performed in which the now tagless enzyme was collected in the flowthrough fractions. Anion-exchange chromatography was subsequently performed, as previously described (28,31) for WT homodimer/heterodimer, ∆16 homodimer/heterodimer and the AdoMetDC LSL-AAA heterodimer, all of which underwent careful binding analyses. Remaining mutants were sufficiently pure after the second Ni 2+ -agarose purification step. Extinction coefficients (Table  S1 ) for the wild-type and mutant enzymes were obtained through the ExPASy-ProtParam program (http://web.expasy.org/protparam/), and used to quantify protein by measuring absorbance at 280 nm. These calculations were performed using the Beer's law equation (A=εlc, where A is absorbance, ε is extinction coefficient, l is the path length and c is concentration).
Expression and purification of ULP-1. The pET15b-ULP1 plasmid was provided by Kim Orth. Expression of this N-terminal His-tagged protease was performed as above with the following modifications: IPTG induction was performed at 30°C O/N, and modified lysis (50 mM Tris-HCl pH 7.5, 350 mM NaCl, 1 mM BME, 10 mM imidazole, 0.2% IGEPAL and 20% glycerol) and purification buffers (buffer A: 50 mM Tris-HCl pH 7.5, 350 mM NaCl, 1mM BME, 10 mM imidazole and 20% glycerol and buffer B: buffer A plus 800 mM imidazole) were used.
Steady-state kinetic analysis. The enzymatic activity of AdoMetDC was assessed using the 14 CO 2 -trapping method (32). AdoMetDC (1 -3 µM homodimers; 0.1 and 1 -6 µM for wild-type and mutant heterodimers, respectively) was titrated into reactions containing 25 µM 14 CO 2 -AdoMet (American Radiolabeled Chemicals), a range of unlabeled AdoMet concentrations (25-1475 µM, Affymetrix), 100 mM Hepes pH 8.0, 50 mM NaCl, 1 mM DTT. Putrescine (5 mM) was included as indicated. Test tubes were capped and placed in a water bath at 37ºC. The CO 2 liberated from the substrate was trapped on a filter paper soaked in 80 µL of saturated Ba(OH) 2 . After 5 min, reactions were quenched using 6 M HCl. The filter paper was then transferred to a scintillation vial containing 5 mL of CytoScint. Samples were placed on the scintillation counter, and the counts per minute (cpm) obtained were converted into velocity (s -1 ) values using the specific activity of the substrate. Data were fitted to the MichaelisMenten equation to determine the steady-state kinetic parameters (k cat , K m ) using Prism (GraphPad, San Diego, CA). The k cat was calculated based on the molecular weight of the dimeric species.
Sedimentation
velocity. All analytical ultracentrifugation (AUC) experiments were performed in a Beckman-Coulter (Indianapolis, IN) Optima XL-I ultracentrifuge using the Beckman An50Ti rotor. Studies were carried out at 20 °C and 50,000 rpm. Samples of co-purified wild-type or mutant AdoMetDC/prozyme were diluted to their final concentrations in AUC buffer (50 mM HEPES pH 8.0, 50 mM NaCl, 1 mM β-mercaptoethanol) and incubated overnight at 4° C before loading into dual-sectored, charcoal-filled Epon centerpieces that had been sandwiched between sapphire windows in a centerpiece housing. The assembled housings were placed in the rotor and allowed to incubate at 20 °C for 2.5 h before centrifugation.
Radially dependent concentration profiles were acquired at approximately 10 min time intervals using the absorption optics tuned to 280 nm.
Data were analyzed using either SEDFIT or SEDPHAT (www.analyticalultracentrifugation.com) and c(s) distributions were used to fit the data (33,34). Regularization levels of 0.68 were used. In the case of the ∆16 mutant, these distributions exhibited strong concentration dependence. Thus, these data were fitted to solutions of the Lamm equation with explicit consideration of the thermodynamics and kinetics of the AdoMetDC/prozyme interaction (35,36). For wild-type AdoMetDC/prozyme mixture, a fixed fraction (23%) of the protein did not participate in the heterodimeric complex, regardless of the concentration of the complex. Based on the method of purification we assumed that this represented a fraction of AdoMetDC that was incompetent to form the complex and that the incompetent fraction was identical and constant in all wild-type and mutant AdoMetDC preparations. In order to carry out analysis of the association of ∆16 and prozyme, six sedimentation experiments were analyzed globally in SEDPHAT, with several other assumptions and constraints: 1) monomeric AdoMetDC and monomeric prozyme behaved identically hydrodynamically, 2) the sedimentation coefficient of the complex was the same as that of the wild-type complex, 3) the material that sediments with an s 20,w -value of 4.9 S is all heterodimeric, with no homodimers of either protein present, 4) no hyper-or hypochromicity accompanied the interaction, 5) all proteins and the complex have the same partial-specific volume (0.73 cm 3 /g), 6 ) an observed 7-S species did not participate in the interaction and could be treated as "non-participating", and 7) the molar ratio of AdoMetDC and prozyme was constant (Fig. S1) . The error interval for the association constant was calculated using the projection method (37) with the F-statistic described by Johnson (38) . All AUC-derived figures were made using GUSSI (biophysics.swmed.edu/MBR/software.html). The same software was used to convert c(s) distributions to standard conditions. SEDNTERP (39) was used to calculate buffer viscosity, buffer density, and protein partial-specific volumes.
Molecular modeling. Human AdoMetDC (PDB code 1I7B (15,18) was displayed using the graphics program PyMOL (40) .
RESULTS

Sequences analysis of eukaryotic AdoMetDCs.
In order to elucidate the structural requirements for AdoMetDC activation by prozyme we performed a sequence alignment of representative AdoMetDCs to identify any sequence signatures that were unique to the trypanosomatid enzymes, and thereby might be involved in prozyme activation. The analysis indicated that the N-terminus contains a unique 16-20 amino acid peptide, present in the trypanosmatid (T. brucei, T. cruzi and Leishmania major) AdoMetDCs, but absent from other eukaryotic homologs (e.g. human and plant; Fig 1B) . In this region, 12 specific amino acids are particularly conserved between the parasitic enzymes. Interestingly, although prozyme contains this stretch of residues as well, the degree of conservation with the respective AdoMetDC or prozyme from different species is lower. The human enzyme is fully active as a homodimer and does not contain this peptide. Thus, this conserved N-terminal extension is only present in the AdoMetDCs that are activated by prozyme, suggesting that it might play a role in the prozyme-mediated activation of the trypanosomatid enzymes.
Unique N-terminus of T. brucei AdoMetDC is essential for activation by prozyme. A mutant version of T. brucei AdoMetDC was constructed lacking the N-terminal 16 amino acids to determine if this region was required for activation. Both homodimeric (Δ16AdoMetDC) and heterodimeric (Δ16AdoMetDC/prozyme) enzymes were expressed and purified from E. coli. Like wild-type AdoMetDC, Δ16AdoMetDC undergoes a self-processing reaction to generate the active enzyme consisting of two chains, α (32kDa) and β (8 kDa) (data not shown). In addition, Δ16AdoMetDC, like the wild-type enzyme, forms a stable complex with wild-type prozyme that co-purified over Ni 2+ -agarose and ion exchange chromatography. In the absence of putrescine, the Δ16AdoMetDC homodimer has a k cat /K m of 16 M -1 s -1 , which is similar to that of the wild-type homodimer, though the K m is increased significantly by this mutation (Table 1, Fig 2) . However, prozyme is unable to activate the mutant enzyme, which displays a catalytic activity for the Δ16AdoMetDC/prozyme heterodimer that is 100-fold lower than the wild-type heterodimer (Fig. 2) . This strong decrease in catalytic efficiency is the consequence of an effect on both the apparent substrate binding constant (K m ) and on the catalytic rate (k cat ) ( Table 1) . Putrescine stimulates the activity of the wild-type AdoMetDC homodimer and has no effect on the heterodimer. Activities of the truncated dimeric enzymes (Δ16AdoMetDC and Δ16AdoMetDC/prozyme) were not significantly affected by the addition of putrescine.
Identification of residues within the N-terminal peptide that are essential for prozyme activation.
To identify specific residues within the N-terminal peptide that were involved in activation by prozyme, Ala-scanning mutagenesis was performed. The key residues were initially narrowed down by construction of four mutants, each containing three consecutive amino acids substituted with Ala, unless the native residue was Ala or Gly, in which case it was unaltered. Similar to the Δ16 homodimer and heterodimer, these mutants were all capable of self-processing and the heterodimeric complexes held together through all purification steps. Kinetic analysis of each mutant was performed on the AdoMetDC/prozyme complex. Results indicate that AdoMetDC triple mutant L8A/S9A/L10A had the strongest effect; the catalytic efficiency was 360-fold lower than for the wild-type enzyme both in the presence and absence of putrescine (Table 1 and Fig 2) . AdoMetDC M11A/M13A showed similarly reduced enzyme activity in the absence of putrescine, but in this case activity was stimulated 20-fold by putrescine to within ~20-fold of wild-type heterodimer levels. The remaining two triple/double mutants (K5A/D6A/S7A and W14A/S16A) were only minimally impaired (3-6-fold) in their ability to be activated by prozyme. To further study the contributions of L8, S9, and L10, individual point mutations to Ala were constructed for each of these residues (Fig 2) . S9 was not essential since activity within 10-fold of wild-type heterodimer levels was observed upon mutation to Ala. However when L8 or L10 were replaced by Ala, the activity was similar to the truncated ∆16AdoMetDC/prozyme complex, though the activity of these mutants was stimulated by putrescine to within 10-fold of wild-type levels.
Analysis of the dimer formation by sedimentation velocity. While all mutant enzymes could be copurified as heterodimers, in order to assess the relative strengths of the associations between the prozyme and various AdoMetDC constructs, we performed AUC experiments in the sedimentation velocity (SV) mode at three different protein concentrations (Fig 3) . Wild-type heterodimer binding affinity (K D ) was compared to those mutations that led to the largest decrease in activity. If the dissociation constant for the heterodimers was near the concentrations used, a concentration-dependence would be expected for the observed sedimentation coefficients or for the populations of the resolved species, whereas if the K d was below the lowest tested concentration no dependence would be observed (41, 42) .
For the wild-type and L8A/S9A/L10A mutant AdoMetDC/prozyme complexes the c(s) distributions, which relate the signal populations of sedimenting species directly to the SV data, revealed two well-resolved peaks (Fig 3a) . The peaks occurred at s 20,w -values of 3.3 S and 4.8 S, and these values were not dependent on the concentration of the complex. The estimated molar masses associated with the two species were 40 kg/mol and 70 kg/mol, consistent with the expected masses for the monomeric (3.3 S) and heterodimeric (4.8 S) species. Significantly, the relative signal populations of the two species did not change over the concentration range studied (0.3 -3.8 µM), demonstrating that these species were not in equilibrium. The lack of relative population variation shows that the dissociation constants were below the lowest complex concentration studied (K d <0.3 µM for wild-type and K d <0.7 µM for the L8A/S9A/L10A mutant). The result for the wild-type enzyme is similar to our prior sedimentation equilibrium analysis, where we found the dissociation constant between AdoMetDC and prozyme to be below 0.5 µM (28). The data also suggest that the 3.3 S material (~23% of the total) contains protein that was no longer competent to form a dimer. SDS-PAGE analysis of the AdoMetDC/prozyme preparations showed that they contain approximately equal concentrations of the two proteins, consistent with the observation that the incompetent material does not represent a major fraction of the protein (Fig.  S1 ). Based on the method of purification excess incompetent prozyme could not be carried through the purification because it lacked a His-tag. This suggests that either the 3.3 S peak contained largely incompetent AdoMetDC or that incompetence occurred after the Ni +2 affinity purification step and the 3.3S material is mixture of incompetent AdoMetDC and prozyme. Two conclusions may be drawn from these data. First, the LSL mutations did not increase the dissociation constant of AdoMetDC and prozyme to above the limit of detection (K d <0.7 µM), and given that this value is well below the concentration used in the enzyme assays these data provide a clear indication that the reduced activity of this mutant does not result from loss of dimerization.
Secondly, the amount of incompetent AdoMetDC in the mutant preparation (~21%) was similar to the wild-type enzyme suggesting its relative abundance does not strongly vary from preparation to preparation. The cause of this phenomenon is unknown.
In contrast to the wild-type and L8A/S9A/L10A protein complexes, ∆16 AdoMetDC/prozyme displayed robust concentration dependence in the SV studies (Fig 3c) . Specifically, when going from low to high concentrations, the signal population (the areas of the peaks in Fig 3c) of the 3.3 S species decreases, while that of the 4.8 S species increases, consistent with mass action law. This observation and our experiences with the wild-type AdoMetDC allowed us to construct a constrained ∆16 + prozyme ↔ ∆16:prozyme interaction model and use it to fit the SV data using the Lamm equation with explicitly considered thermodynamics and kinetics (see experimental procedures section for the assumptions and constraints built into the model). Given the assumptions and constraints, we found that the dissociation constant was 1.0 [0.9-1.4] µM (the numbers in brackets indicate the 68.3% error interval). The quality of the fits to the data was high based on the low overall root-mean-square of the differences between the data and the fits (0.0065 AU) and the non-systematic nature of the residuals (Fig. S2) . Our ability to resolve the complex from the uncomplexed material in the c(s) distributions indicates a slow off rate for the interaction. Thus, while wild-type and the triple mutant heterodimers bind tightly, there is decreased affinity between subunits in the ∆16 heterodimer. This implies that truncation at the Nterminus weakens the dimer interface, but that it does not block dimer formation.
To further confirm that poor dimer formation did not contribute to the lack of activation of the ∆16 heterodimer, an enzyme concentration titration (1 -32 µM) was performed using the kinetic activity assay. Results demonstrate that as the concentration of ∆16 AdoMetDC/prozyme was doubled, the enzyme velocity also doubled and there was no indication of a greater than proportional increase in rate as would be expected if monomers were contributing to the lowered rate of the reaction. Thus, based on the sedimentation velocity results, the ∆16 truncation at the Nterminus weakens the dimer interface, but the dimer was fully formed under the conditions of the enzyme assay. These data suggests that the presence of substrate may impact the K d for dimerization of the ∆16 mutant.
N-terminus of T. brucei prozyme is not involved in
AdoMetDC activation. Since T. brucei prozyme also contains residues at the N-terminus with similarity, though not full conservation, to the trypanosomatid AdoMetDC N-terminal signature, we evaluated the effects of truncation of the prozyme N-terminus as well. Results demonstrate that when wild-type AdoMetDC is co-purified with ∆25 prozyme, a catalytically efficient enzyme was still obtained (Table 1 and Fig 4) . Similarly to wild-type prozyme, ∆25 prozyme was not able to stimulate ∆16 AdoMetDC activity, demonstrating once again the essentiality of the AdoMetDC Nterminus for AdoMetDC activation. Putrescine had no affect on the activity of these complexes.
DISCUSSION
Regulation of polyamine biosynthesis is a key cellular function and eukaryotic cells have evolved a wide range of transcriptional, translational and posttranslational mechanisms to control pathway flux, including several mechanisms that are unique to the polyamine pathway (11) . While trypanosomatids do not utilize the mechanisms demonstrated for mammals, yeast and plants, they too have evolved a novel species-specific mechanism for regulation that relies on enzyme activation of a catalytically impaired AdoMetDC subunit with an inactive paralog, termed prozyme (20). The structural basis for the substantial activation (~10 3 -fold) that is observed upon heterodimer formation has been partially elucidated by our current studies. We found that the trypanosomatid AdoMetDCs contain a conserved N-terminal peptide of 12 nearly invariant residues that are not present in other eukaryotic AdoMetDCs, none of which are regulated by a prozyme mechanism. Truncation of these residues, or point mutation of L8, L10, or of M11 and M13 in combination, led to a loss of T. brucei AdoMetDC prozyme activation despite the finding that the heterodimer was still formed. These data demonstrate that the conserved Nterminal peptide is essential for the activation process.
The N-terminus of T. brucei AdoMetDC could potentially have played a role in AdoMetDC activation by prozyme either by promoting dimer formation or through an allosteric regulatory mechanism. Our results are consistent with the second possibility. Firstly, while a number of the mutant enzymes that contain either truncations or point mutations in the N-terminus of AdoMetDC are no longer activated by prozyme, they all form heterodimers that co-purify over multiple steps of column chromatography. Secondly, sedimentation velocity experiments on the AdoMetDC L8A/S9A/L10A mutant show that despite the lack of activation, this protein forms a dimer with prozyme that is apparently as strong as the wildtype heterodimer. Thirdly, while the ∆16 heterodimer does form a weaker dimer, we found no evidence that this dissociation occurs under the conditions of the enzyme assay. Thus the data suggest that these N-terminal residues influence catalysis through an allosteric mechanism. Structural knowledge about AdoMetDC relies on the human homodimeric enzyme, which is activated by putrescine and does not have an Nterminal extension. T. brucei AdoMetDC shares 58% sequence identity with human AdoMetDC and, while the expected tertiary structure will be similar, the position of the N-terminus of T. brucei AdoMetDC cannot be predicted with existing data. However, the N-terminus of human AdoMetDC (residues 5-7) (Fig. 1) lines the substrate-binding pocket, suggesting the more extensive N-terminal sequence of T. brucei could potentially fold back to interact with the active site. Thus, our data suggest a model in which binding of prozyme results in a conformational change that rearranges the N-terminus closer to the active site residues, allowing new interactions that enhance catalysis (Fig 5) . Such a mechanism is reminiscent of the conversion of trypsinogen into its active form trypsin, which is achieved after hydrolysis of the Lys (15)-Ile (16) bond by enterokinase (43) . This cleavage leads to the formation of a new Nterminus, which rearranges and places key amino acids closer to the residues that form the oxyanion hole (Gly193 and Ser195). The AdoMetDC Nterminus is not near the dimer interface so the mechanism by which heterodimerization impacts the conformation of the N-terminal 16 amino acids likely involves long-range interactions as has been observed in other proteins (44) .
The role of putrescine in activating trypanosomatid AdoMetDCs differs between wildtype T. brucei AdoMetDC and N-terminal AdoMetDC mutants, and between the trypanosomatid enzymes from different species. While the T. brucei AdoMetDC homodimer is marginally activated by putrescine, the heterodimer is not affected (Fig. 5A) . In contrast, for the T. cruzi enzyme, putrescine activates both the homodimer and the heterodimer and both are required for full activation (29). In this study we found that the M11A/M13A, L8A and L10A mutant heterodimers, but not the ∆16 heterodimer, have become sensitive to putrescine, and these enzymes are now partially activated by the diamine. Our data suggest that mutation of the T. brucei AdoMetDC N-terminal residues leads to population of additional conformational states that are responsive to putrescine activation, leading to partially active conformations that are not observed in the wild-type enzyme (Fig. 5B) . The wild-type T. cruzi heterodimeric enzyme must also populate additional partially active conformations that are not typically observed for the wild-type T. brucei enzyme. Our data suggest that there is an inner dependence between putrescine and prozyme binding, and that both have the potential to influence the equilibrium between active and inactive conformers.
In the human enzyme, the putrescine-binding site is composed of acidic residues (D174, E178, E256) distant from the active site, and closer to the dimer interface. Structural studies demonstrate that putrescine influences the orientation of essential catalytic residues through a hydrogen-bonding network, mediated by K80, H243, E11 and S229 (45) . However, although D174 and E256, in addition to some of the residues involved in connecting the putrescine-binding pocket to the active site, are conserved between the trypanosomatid and human enzymes, they do not seem to play the same roles. We previously showed that, similarly to the human enzyme, D174 is essential for putrescine to bind T. cruzi AdoMetDC and stimulate its activity, while the remaining amino acids known to be important in the human enzyme were not, supporting an alternative binding mode for putrescine to the trypanosomatid enzymes (46) .
T. brucei AdoMetDC has been both genetically and chemically validated as a potential drug target for the treatment of HAT (20). The finding that AdoMetDC is regulated by a catalytically dead homolog provides alternative mechanisms to active-site targets for the design of speciesselective enzyme inhibitors. The discovery that the N-terminus of AdoMetDC is involved in an allosteric mechanism for prozyme activation indeed suggests several such approaches. Small molecules could be designed to block interaction between the peptide and key residues during catalysis or compounds that block the conformational change that accompanies activation could also be sought. Gleevec, a drug used for the treatment of certain cancers including chronic myelogenous leukemia (CML), is an inhibitor of the constitutively active Bcr-Abl tyrosine kinase (47, 48) . Its mechanism of action represents a good example of a ligand exploiting the inactive conformation of a protein kinase. Another example for this type of mechanism is the development of bi-aryl urea inhibitors of P38 MAP kinase (49) . More detailed structural information on the T. brucei AdoMetDC/prozyme heterodimeric enzyme is needed to fully elucidate the allosteric mechanism of prozyme activation and to allow these approaches to be fully explored.
ABBREVIATIONS.
AdoMetDC AdoMetDC/prozyme heterodimer. Distributions were normalized by the total amount of signal present between 2 S and 6 S and slowly sedimenting material of < 1 S has been excluded. The concentrations of the (potential) complex were 0.7 µM (red), 1.9 µM (black), and 3.3 µM (blue). Multiple low activity and partially active conformations may be present and not all low activity or partially active forms may be structurally equivalent. B.
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